Tyra prices $400 million stock and pre-funded warrant offering at $22.03 per share
On September 14, 2026, Tyra Biosciences agreed to sell 9,079,000 shares of common stock and pre-funded warrants for 9,078,529 shares, with gross proceeds expected to be approximately $400.0 million before underwriting discounts and offering expenses. The offering is expected to close on September 15, 2026, and the company plans to use the net proceeds, together with existing cash, to advance its dabogratinib 3x3 development strategy, support preclinical and discovery programs, and fund working capital and general corporate purposes. Issuing these shares and warrants will dilute existing shareholders.
Key points
- Offering of 9,079,000 common shares at $22.03 per share, plus pre-funded warrants for 9,078,529 shares at $22.029 per warrant
- Underwriters agreed to buy the shares at $20.7082 per share; gross proceeds expected to be approximately $400.0 million
- Closing expected September 15, 2026; proceeds targeted at dabogratinib 3x3 in LG-UTUC, IR NMIBC and achondroplasia
The filing
Written by AI on Nov 9, 2026, 11:45 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 14, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.